Clinical trial
A Phase 2 Study of Paclitaxel Plus Rivoceranib in Patients With GIST With a High P-glycoprotein Expression After Failure With at Least Imatinib, Sunitinib and Regorafenib
NCT05905887 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Paclitaxel Plus Rivoceranib in Patients With GIST With a High P-glycoprotein Expression After Failure With at Least Imatinib, Sunitinib and Regorafenib
- Lead sponsor
- Asan Medical Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 6, 2023
- Completion date
- December 31, 2027
- Enrollment
- 48 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.